A Phase 3 interventional study of Clopidogrel and placebo in Heart Defects, Congenital, sponsored by Sanofi. Completed at 15 sites in 15 countries. Open to participants aged 12 Months and older. Per ClinicalTrials.gov, last updated 2011-08-22.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 356 studies in Heart Defects, Congenital with a site in United States — 66 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.
Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 93rd largest by enrollment of the 184 interventional ones that give a count, is one of 11 that started in 2009, is one of 19 in phase 3, and was the 80th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 251 are open to participants now.
Browse Heart Defects, Congenital studies →66 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 1 mo–3 yrs
Le Bonheur Children's Hospital · Sites in United States
Ages 0 mo–12 mo
Carelon Research · Sites in United States
Ages 18+
Carelon Research · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.
This study: 12 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
356 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 33 · Phase 3 25 · Phase 4 9
First in 1980; this study’s year is marked. 11 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 60 across 507 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 50 across the 184 interventional studies, 72 across the 167 observational. Of the 240 that completed or were terminated, 62 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 356 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 3 studies filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
31 of the studies in Heart Defects, Congenital with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04216927Phase 3Children's Hospital Medical Center, CincinnatiNO During CPB in Neonates to Reduce Risk of AKI | 2027-06-30 |
| NCT05077774Medtronic CardiovascularHarmony TPV Post-Approval Study | 2026-11 |
| NCT05687292Boston Children's HospitalApplication of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery in Children | 2026-11-18 |
| NCT07559253University of Wisconsin, MadisonImplementation of an Accessible Healthcare Model (ACHD STRONG): Comparing Nurse and Physician Lead Healthcare Transition Education in a RE-AIM Framework | 2026-11-30 |
| NCT04236479Catherine BollardMesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP) | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 356 studies in Heart Defects, Congenital with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is the extension of the CLARINET study [NCT00396877 -EFC5314] in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt.
The primary objective was to assess the safety up to 18 months of age of the extended use of Clopidogrel 0.2 mg/kg/day in patients for whom the shunt was still in place at one year of age.
The secondary objective was to assess the efficacy on the occurrence of shunt thrombosis requiring intervention or any death.
Patients remained in the treatment group to which they were originally allocated for the CLARINET study and continued blindly their treatment (0.2 mg/kg/day of clopidogrel or placebo) up to the occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first. The maximum treatment duration were 6 months.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.2 mL/kg/day matching placebo solution once daily.
Drug: placebo
0.2 mL/kg/day Clopidogrel reconstituted solution at 1mg/mL once daily.
Drug: Clopidogrel
Form: reconstituted solution using Clopidogrel powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight
Also known as: SR25990, Plavix
Form: reconstituted solution using matching placebo powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight
Number of Participants With Bleeding Events
All bleeding events experienced during the study period were collected as for any Adverse Event. The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted.
Time frame: Up to a maximum of 6 months
Number of Participants According to Bleeding Type/Etiology
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology.
Time frame: Up to a maximum of 6 months
Number of Participants With Shunt Thrombosis Requiring Intervention or Deaths
Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded. Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first).
Time frame: Up to a maximum of 6 months
49 participants were enrolled between January 2009 and January 2010 in 25 sites in 15 countries (7 countries involved in CLARINET study were not selected as the delay in obtaining IRB/IEC and Health Authorities approvals would prevent recruitment and/or no patient would be recruited as the second surgery is always performed before 1 year of age).
| Milestone | Placebo | Clopidogrel 0.2 mg/kg/Day |
|---|---|---|
| Started | 23 | 26 |
| Treated | 23 | 26 |
| Completed treatment | 22 | 24 |
| Completed | 23 | 25 |
| Not completed | 0 | 1 |
| Withdrew: Parent(s)/guardian(s)'s request | 0 | 1 |
All bleeding events experienced during the study period were collected as for any Adverse Event. The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted.
| participants | Placebo | Clopidogrel 0.2 mg/kg/Day |
|---|---|---|
| Any bleeding event | 0 | 2 |
| - Serious | 0 | 0 |
| - Serious with an outcome of death | 0 | 0 |
| - Leading to permanent treatment discontinuation | 0 | 0 |
Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded. Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first).
| participants | Placebo | Clopidogrel 0.2 mg/kg/Day |
|---|---|---|
| shunt thrombosis requiring intervention | 0 | 0 |
| death | 1 | 0 |
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology.
| participants | Placebo | Clopidogrel 0.2 mg/kg/Day |
|---|---|---|
| Spontaneous | 0 | 1 |
| Puncture (vascular access site) | 0 | 1 |
Collected over Up to a maximum of 6 months. All Adverse Events (AE) experienced during the study period were collected regardless of seriousness or relationship to the drug .. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/23 (13%) | 7/23 (30.4%) |
| Clopidogrel 0.2 mg/kg/Day | — | 6/26 (23.1%) | 17/26 (65.4%) |
| Event | Placebo | Clopidogrel 0.2 mg/kg/Day |
|---|---|---|
| Diaphragmatic paralysisRespiratory, thoracic and mediastinal disorders | 1/23 | 0/26 |
| Pulmonary artery stenosisRespiratory, thoracic and mediastinal disorders | 1/23 | 0/26 |
| Ischaemic strokeNervous system disorders | 1/23 | 0/26 |
| BronchiolitisInfections and infestations | 0/23 | 1/26 |
| Croup infectiousInfections and infestations | 0/23 | 1/26 |
| GastroenteritisInfections and infestations | 0/23 | 1/26 |
| Urinary tract infectionInfections and infestations | 0/23 | 1/26 |
| Viral infectionInfections and infestations | 0/23 | 1/26 |
| Low cardiac output syndromeCardiac disorders | 0/23 | 1/26 |
| Nodal arrhythmiaCardiac disorders | 0/23 | 1/26 |
| Event | Placebo | Clopidogrel 0.2 mg/kg/Day |
|---|---|---|
| Any infections and infestationsInfections and infestations | 6/23 | 14/26 |
| Upper respiratory tract infectionInfections and infestations | 0/23 | 6/26 |
| Any gastrointestinal disordersGastrointestinal disorders | 2/23 | 6/26 |
| Any general disorders and administration site conditionsGeneral disorders | 1/23 | 6/26 |
| PyrexiaGeneral disorders | 0/23 | 4/26 |
| Any respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 1/23 | 4/26 |
| PharyngitisInfections and infestations | 3/23 | 1/26 |
| DiarrhoeaGastrointestinal disorders | 1/23 | 3/26 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/23 | 3/26 |
| Any injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 1/23 | 3/26 |
| Age Continuous(days) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| at randomization in CLARINET study | 45.2 ± 26.1 | 33.1 ± 20.5 | 38.8 ± 23.8 |
| at inclusion | 368.1 ± 4.2 | 368.0 ± 2.7 | 368.0 ± 3.5 |
| Sex: Female, Male(Participants) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Female | 10 | 14 | 24 |
| Male | 13 | 12 | 25 |
| Region of Enrollment(participants) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| United States | 0 | 1 | 1 |
| Portugal | 3 | 1 | 4 |
| Taiwan | 4 | 5 | 9 |
| Spain | 0 | 2 | 2 |
| Russian Federation | 1 | 0 | 1 |
| United Kingdom | 1 | 2 | 3 |
| Italy | 0 | 1 | 1 |
| India | 0 | 1 | 1 |
| France | 0 | 1 | 1 |
| Hungary | 2 | 1 | 3 |
| Mexico | 6 | 4 | 10 |
| Brazil | 4 | 2 | 6 |
| Malaysia | 1 | 1 | 2 |
| Poland | 1 | 1 | 2 |
| Germany | 0 | 3 | 3 |
| Weight at inclusion(kilograms (kg)) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Mean | 7.9 ± 1.1 | 8.1 ± 1.2 | 8.0 ± 1.2 |
| Height at inclusion(centimeters (cm)) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Mean | 71.8 ± 2.8 | 70.0 ± 10.4 | 70.8 ± 7.8 |
| Type of initial shunt palliation(participants) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Modified Blalock Taussig Shunt with Norwood | 0 | 1 | 1 |
| Modified Blalock Taussig Shunt without Norwood | 18 | 20 | 38 |
| Sano procedure with Norwood | 0 | 0 | 0 |
| Sano procedure without Norwood | 1 | 1 | 2 |
| Central shunt | 1 | 3 | 4 |
| Stent of ductus arteriosus | 3 | 1 | 4 |
| Shunt on cardiopulmonary bypass(participants) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Yes | 2 | 5 | 7 |
| No | 21 | 21 | 42 |
| Age at shunt palliation(days) | Placebo | Clopidogrel 0.2 mg/kg/Day | Total |
|---|---|---|---|
| Mean | 25.7 ± 28.7 | 13.7 ± 12.7 | 19.4 ± 22.3 |
The record gives a start of Jan 2009, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel